Will Ebiefung

About the Author Will Ebiefung

Will Ebiefung studied finance and accounting at the University of Tennesee. He works as a freelance investment analyst focusing on equities with market caps below $100 million. In addition to writing, Will is a full-time investor focusing on web properties and debt-based securities.

Mad at DryShips Inc. (DRYS)? Join the Club

DryShips Inc. (NASDAQ:DRYS) has been the recipient of numerous legal actions and investigations.

Valeant Pharmaceuticals Intl Inc: The Problem with Branded Rx

The closing of the $820 million divestiture of Dendreon to Sanpower Group boosts Valeant Pharmaceuticals Intl Inc (NYSE:VRX) liquidity position, but it does nothing …

Explaining Bitcoin Investment Trust’s (GBTC) Premium Over NAV

The Bitcoin Investment Trust (OTCMKTS:GBTC) is the first publicly traded security designed to track the performance of Bitcoin, and it does so for …

Tesla Inc (TSLA): The Model 3 Vs. the Model S

New details emerge about Tesla Inc (NASDAQ:TSLA) Model 3 sedan, the new mass-market electric vehicle expected to be available by the end of …

Valeant Pharmaceuticals Intl Inc (VRX) Risk/Reward Remains Problematic

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a difficult stock to value. Unlike a ‘regular’ company with a stock price reflecting cash flow, EPS, …

DryShips Inc. (DRYS) New Credit Facility Won’t Stop the Stock from Sinking

DryShips Inc. (NASDAQ:DRYS) looks like it is in a death spiral, and after countless dilutions and stock splits, even the most stubborn bulls …

Why Apple Inc. (AAPL) Doesn’t Need to Repatriate Its Cash

Trump’s victory in the U.S presidential election put a new gust of wind in Apple Inc.

Snap Inc (SNAP) Business Model Is Flawed; Here’s Why

I was widely encouraged to invest in Snap Inc (NYSE:SNAP) when the stock IPOed in March. Many of my friends made the mistake …

Apple Inc. (AAPL): Establishing a Foothold in India

Apple Inc. (NASDAQ:AAPL) international iPhone sales are in trouble because of China where revenue fell 14% year-on-year in the March quarter.

Valeant Pharmaceuticals Intl Inc (VRX) Struggles with Generic Competition

Valeant Pharmaceuticals Intl Inc’s (NYSE:VRX) Branded Rx division has been making headlines as the embattled drugmaker struggles to prevent generic competition from eroding …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts